Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
.webp)
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Imdelltra (tarlatamab-dlle) is a bispecific antibody that binds simultaneously to DLL3 (delta-like ligand 3), a protein expressed on the surface of most small cell lung cancer cells, and to CD3 on the surface of T cells, redirecting the patient's own T cells to recognize and destroy DLL3-expressing tumor cells. It is indicated for the treatment of:
Imdelltra received full traditional FDA approval in November 2025, after initially being granted accelerated approval in May 2024 based on response rate and duration of response; the confirmatory Phase 3 DeLLphi-304 trial supported conversion to full approval. Imdelltra is a prescription anticancer medicine and must be administered under the supervision of a qualified medical oncologist, in a setting equipped to recognize and manage CRS and neurologic toxicity.
Imdelltra is given as a fixed-dose intravenous infusion over 1 hour, following a step-up dosing schedule in Cycle 1 to reduce the risk of CRS:
Premedication with dexamethasone is given before each infusion in Cycle 1, along with post-infusion IV hydration on Days 1, 8, and 15. Patients are generally monitored in an appropriate healthcare setting for approximately 22–24 hours after the first two doses (Cycle 1, Day 1 and Day 8). They are advised to remain within about 1 hour of such a facility, accompanied by a caregiver, for 48 hours from the start of each of the first two infusions.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
IMDELLTRA (tarlatamab-dlle) injection may be imported in the patient's name only, by patients or government hospitals. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.
IMDELLTRA (tarlatamab-dlle injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, IMDELLTRA is not commercially marketed in India.
However, patients in India can legally access IMDELLTRA through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.
NamedPatientProgram.com (NPP) acts as a facilitator under named patient supply, providing input on:
IMDELLTRA can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only upon receipt of a valid doctor's prescription and, where applicable, an import permit.
NamedPatientProgram.com (NPP) can source Imdelltra from reliable global manufacturers and qualified pharmaceutical supply channels and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Imdelltra requires cold-chain handling throughout transit.
All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For Imdelltra cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access Imdelltra® through regulated import pathways, with delivery arranged to the treating hospital based on a valid oncologist's prescription.
A major oncology and thoracic cancer hub with institutions like Tata Memorial, Mumbai, sees high demand for advanced lung cancer therapies like Imdelltra®. Access is often coordinated for patients with relapsed small cell lung cancer.
With a growing network of multispecialty hospitals, Bangalore supports access to global oncology treatments through structured import pathways guided by treating specialists.
As part of the Delhi NCR region, the city has a strong concentration of cancer centers and thoracic oncology specialists, making it a key location for accessing advanced imported therapies.
Home to leading hospitals like Medanta, Gurgaon plays an important role in facilitating access to innovative lung cancer treatments through coordinated care pathways.
With proximity to Delhi and access to top hospitals, Noida patients benefit from streamlined logistics and specialist-driven treatment planning.
Hyderabad's advanced healthcare infrastructure and oncology expertise support patients seeking access to internationally approved cancer therapies.
Known for its established medical ecosystem, Chennai attracts patients from across India for complex lung cancer treatments and specialized drug access.
A key eastern healthcare hub, Kolkata offers access to advanced oncology care through leading hospitals and treatment centers.
Ahmedabad's expanding healthcare sector and oncology facilities support patients requiring advanced and imported cancer therapies.
With reputed hospitals and a growing cancer care infrastructure, Pune is an emerging center for access to specialized oncology treatments.
Serving North India, Chandigarh provides access to advanced medical care through reputed institutions and specialist-led treatment planning.
Jaipur's improving healthcare network enables patients to explore access to innovative cancer therapies through structured import processes.
As a major city in North India, Lucknow supports access to advanced oncology treatments through both public and private healthcare institutions.
Indore is emerging as a regional healthcare hub, offering access to specialized cancer care and modern treatment pathways.
Patients in Bhopal can access advanced cancer treatments through the growing healthcare infrastructure and referral networks.
Nagpur serves as a central hub for patients across Vidarbha, with increasing access to oncology care and specialized therapies.
Surat's developing healthcare ecosystem supports patients seeking access to global oncology treatments through coordinated care.
As a major city in Eastern India, Patna provides growing access to cancer treatment through expanding hospital networks.
Coimbatore is known for quality healthcare services, offering access to advanced oncology treatments in South India.
With modern hospitals and specialist care, Kochi enables patients to explore access to internationally approved cancer therapies.
Note: Access timelines may vary depending on documentation, regulatory approvals, and sourcing logistics.
Imdelltra® is typically used in advanced thoracic oncology settings and can be accessed at leading hospitals across India, where specialists guide treatment decisions and coordinate patient-specific access pathways.
One of India's premier cancer institutes, Tata Memorial plays a key role in treating complex lung cancer cases and guiding patients toward advanced therapies like Imdelltra®.
As a leading government medical institution, AIIMS provides comprehensive cancer care and supports patients requiring access to specialized and emerging treatments.
With a nationwide presence, Apollo Hospitals offers advanced oncology services and facilitates access to global treatment options through its extensive medical network.
Fortis hospitals are equipped with modern cancer care facilities and multidisciplinary teams that manage complex treatment pathways for patients.
Max Healthcare is known for its strong oncology and pulmonology departments, providing access to innovative therapies under expert clinical supervision.
Manipal Hospitals supports advanced cancer care through experienced specialists and structured treatment planning across multiple cities.
A leading private hospital in Mumbai, Kokilaben Hospital offers cutting-edge oncology care and access to advanced global therapies.
Medanta is a renowned super-specialty hospital where complex lung cancer cases are managed with advanced treatment protocols and global access support.
BLK-Max provides comprehensive oncology services and supports patients seeking access to specialized treatment options.
A dedicated cancer care center, RGCI focuses on advanced oncology treatments and supports patients through complex treatment journeys.
HCG is a specialized cancer hospital network known for its focus on precision oncology and advanced treatment modalities.
Narayana Health combines affordability with advanced medical care, offering oncology services across multiple locations in India.
Amrita Hospital provides high-quality cancer care with a focus on patient-centric treatment and access to modern therapies.
Yashoda Hospitals are known for their strong oncology departments and advanced treatment infrastructure in South India.
A well-established hospital in Delhi, Sir Ganga Ram provides multidisciplinary cancer care supported by experienced specialists.
CARE Hospitals provide modern oncology treatment facilities and multidisciplinary care across multiple cities.
Note: Imdelltra® is not stocked for direct purchase but is arranged through compliant import processes and delivered to the hospital for patient-specific treatment.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
